Uutela, Aki http://orcid.org/0000-0003-1324-5894
Osterlund, Emerik
Halonen, Päivi
Kallio, Raija
Ålgars, Annika
Salminen, Tapio
Lamminmäki, Annamarja
Soveri, Leena-Maija
Ristamäki, Raija
Lehtomäki, Kaisa http://orcid.org/0000-0002-2994-1459
Stedt, Hanna
Heervä, Eetu
Muhonen, Timo
Kononen, Juha
Nordin, Arno
Ovissi, Ali
Kytölä, Soili
Keinänen, Mauri
Sundström, Jari
Nieminen, Lasse
Mäkinen, Markus J.
Kuopio, Teijo
Ristimäki, Ari
Isoniemi, Helena
Osterlund, Pia http://orcid.org/0000-0002-7124-3515
Article History
Received: 14 February 2022
Revised: 10 April 2022
Accepted: 10 May 2022
First Online: 24 May 2022
Competing interests
: All authors report institutional research funding from Eli Lilly, Merck KGaA, Roche Oy, Sanofi and unrestricted grants from Amgen and Servier, during the conduct of the study. AU, EO, PH, RK, AÅ, TS, AL, LMS, RR, KL, HS, EH, TM, JK, AN, AO, AK, MK, JS, LN, MM, TK, AR, HI and PO report grants, personal fees or non-financial support from Abbvie, Amgen, Astra-Zeneca, Baxalta/Shire, Bayer, BMS, Celgene, Eisai/Ewopharma, Eli Lilly, Erythech Pharma, Fresenius, Incyte, Jansen-Cilag, Medicom, Merck, MSD, Nordic Drugs/Pharma, Novartis, Nutricia/Danone, Pierre-Fabre, Roche Oy, Sanofi, Servier, Sobi and/or Varian.
: This study was conducted in accordance with the declaration of Helsinki and monitored independently. The study protocol was approved by the Ethics Committee at Helsinki University Hospital (242/13/03/02/2011 and HUS/1288/2016) and all patients provided written informed consent.
: All authors had full access to the data and had final responsibility for the decision to submit for publication, and all authors have accepted the manuscript and the decision to submit it for publication. No individual patients can be recognised in the publication.